Prescient Therapeutics Limited (ASX:PTX) Insider James Campbell Buys 750,000 Shares

Prescient Therapeutics Limited (ASX:PTX) insider James Campbell bought 750,000 shares of Prescient Therapeutics stock in a transaction dated Monday, August 4th. The stock was acquired at an average cost of A$0.04 ($0.03) per share, with a total value of A$30,000.00 ($19,607.84).

Prescient Therapeutics Price Performance

The firm has a market cap of $38.66 million, a PE ratio of -4.69 and a beta of 1.19. The company has a debt-to-equity ratio of 1.83, a current ratio of 8.08 and a quick ratio of 17.31.

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations.